I might add this, will diabetics become more depressed if they can’t control their glucose? We don’t want to add to depression, but I would like to know what ingredients in the drug could substantiate depression? If the drug is working in Europe and doing a better job, how long do we need to study to be clear that it is in fact the drug that is creating depression and perhaps not something in the individual’s DNA as a contributing factor? Just some questions that come to mind…BD
Sanofi-Aventis said that a trial of Acomplia showed a significant improvement in glucose control in comparison to insulin among patients with type 2 diabetes. Glucose control was three times more pronounced among the Acomplia group compared to volunteers who received insulin and lifestyle advice. The drug has been approved in Europe but faces a lengthy delay in the U.S. as regulators shift through data that the drug may raise the risk of depression. In the trial, 14 percent of the Acomplia drug reported symptoms of anxiety compared to five percent in the control group and 14 percent reported symptoms of depression compared to 7.5 percent in the control arm.
Sanofi: Acomplia demonstrates better glucose control - FierceBiotech
0 comments :
Post a Comment